Interstitial high-dose rate brachytherapy as boost for anal canal cancer

Radiation Oncology

Jean-Michel Hannoun-Levi²  Jean-Pierre Gerard¹  Mathieu Gautier¹  Eric François³  Karen Benezery¹  Audrey Claren²  Alexander Tuan Falk² 

[1] Department of Radiation Therapy, Antoine Lacassagne Cancer Center, 33, Avenue de Valombrose, Nice, 06189, Cedex, France;University of Nice Sophia-Antipolis, Nice, France;Departement of Medical Oncology, Antoine Lacassagne Cancer Center, Nice, France

关键词: Radiotherapy;    Boost;    High-dose rate;    Anal canal cancer;    Brachytherapy;   

Others  :  1228546
DOI  :  10.1186/s13014-014-0240-4

 received in 2014-02-15, accepted in 2014-10-16,  发布年份 2014

【 摘 要 】

Aim

To assess clinical outcomes of patients treated with a high-dose rate brachytherapy boost for anal canal cancer (ACC).

Methods

From August 2005 to February 2013, 28 patients presenting an ACC treated by split-course external beam radiotherapy (EBRT) and HDR brachytherapy with or without chemotherapy in a French regional cancer center in Nice were retrospectively analyzed.

Results

Median age was 60.6 years [34 ¿ 83], 25 patients presented a squamous cell carcinoma and 3 an adenocarcinoma; 21 received chemotherapy. Median dose of EBRT was 45 Gy [43.2 ¿ 52]. Median dose of HDR brachytherapy was 12 Gy [10 - 15] with a median duration of 2 days. Median overall treatment time was 63 days and median delay between EBRT and brachytherapy was 20 days. Two-year local relapse free, metastatic free, disease free and overall survivals were 83%, 81.9%, 71.8% and 87.7% respectively. Acute toxicities were frequent but not severe with mostly grade 1 toxicities: 37% of genito-urinary, 40.7% of gastro-intestinal and 3.7% of cutaneous toxicities. Late toxicities were mainly G1 (43.1%) and G2 (22%). Two-year colostomy-free survival was 75.1%, one patient had a definitive sphincter amputation.

Conclusion

High-dose rate brachytherapy for anal canal carcinoma as boost represents a feasible technique compared to low or pulsed-dose rate brachytherapy. This technique remains an excellent approach to precisely boost the tumor in reducing the overall treatment time.

【 授权许可】

   
2014 Falk et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figures 2.

Figures 3.

Figure 4.

【 参考文献 】

• [1]Faivre J, Trama A, De Angelis R, Elferink M, Siesling S, Audisio R, Bosset JF, Cervantes A, Lepage C: Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995¿2002. Eur J Cancer 2012, 48:1417-1424.
• [2]Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, Peiffert D, van Glabbeke M, Pierart M: Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol Off J Am Soc Clin Oncol 1997, 15:2040-2049.
• [3]UKCCCR Anal Cancer Trial Working Party: Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research Lancet 1996, 348:1049-1054.
• [4]Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin.Lancet 1996, 348:1049¿1054.
• [5]Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S, Jitlal M, Ledermann J: Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer 2010, 102:1123-1128.
• [6]Myerson RJ, Garofalo MC, Naqa IE, Abrams RA, Apte A, Bosch WR, Das P, Gunderson LL, Hong TS, Kim JJJ, Willett CG, Kachnic LA: Elective clinical target volumes for conformal therapy in anorectal cancer: an RTOG consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 2009, 74:824-830.
• [7]Peiffert D, Giovannini M, Ducreux M, Michel P, François E, Lemanski C, Mirabel X, Cvitkovic F, Luporsi E, Conroy T, Gérard J-P: High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: Final results of a phase II study. Ann Oncol 2001, 12:397-404.
• [8]Kachnic LA, Winter K, Myerson RJ, Goodyear MD, Willins J, Esthappan J, Haddock MG, Rotman M, Parikh PJ, Safran H, Willett CG: RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 2013, 86:27-33.
• [9]Papillon J, Montbarbong JF, Gerard JP, Chassard JL, Ardiet JM: Interstitial curietherapy in the conservative treatment of anal and rectal cancers. Int J Radiat Oncol 1989, 17:1161-1169.
• [10]Bruna A, Gastelblum P, Thomas L, Chapet O, Bollet MA, Ardiet J-M, Gérard J-P, Peiffert D: Treatment of squamous cell anal canal carcinoma (SCACC) with pulsed dose rate brachytherapy: A retrospective study. Radiother Oncol 2006, 79:75-79.
• [11]Hoskin PJ, Colombo A, Henry A, Niehoff P, Paulsen Hellebust T, Siebert F-A, Kovacs G: GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. Radiother Oncol J Eur Soc Ther Radiol Oncol 2013, 107:325-332.
• [12]Viswanathan AN, Thomadsen B: American Brachytherapy Society Cervical Cancer Recommendations Committee, American Brachytherapy Society: American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles. Brachytherapy 2012, 11:33-46.
• [13]Kolotas C, Zamboglou N: Role of interstitial brachytherapy in the treatment of malignant disease. Onkologie 2001, 24:222-228.
• [14]NCI Term Browser. [http://nciterms.nci.nih.gov/ncitbrowser/pages/vocabulary.jsf?dictionary=Common%20Terminology%20Criteria%20for%20Adverse%20Events]
• [15]Kapoor R, Khosla D, Shukla AK, Kumar R, Gupta R, Oinam AS, Sharma SC: Dosimetric and clinical outcome in image-based high-dose-rate interstitial brachytherapy for anal cancer.Brachytherapy 2013. no 4 (July 2014): 388-93. doi:10.1016/j.brachy.2013.09.006.
• [16]Vordermark D, Flentje M, Sailer M, Kölbl O: Intracavitary afterloading boost in anal canal carcinoma. Results, function and quality of life. Strahlenther Onkol Organ Dtsch Röntgenges Al 2001, 177:252-258.
• [17]Doniec JM, Schniewind B, Kovács G, Kahlke V, Loehnert M, Kremer B: Multimodal therapy of anal cancer added by new endosonographic-guided brachytherapy. Surg Endosc 2006, 20:673-678.
• [18]Oehler-Jänne C, Seifert B, Lütolf UM, Studer G, Glanzmann C, Ciernik IF: Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma. Brachytherapy 2007, 6:218-226.
• [19]Saarilahti K, Arponen P, Vaalavirta L, Tenhunen M: The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer. Radiother Oncol 2008, 87:383-390.
• [20]Gerard J-P, Mauro F, Thomas L, Castelain B, Mazeron J-J, Ardiet J-M, Peiffert D: Treatment of squamous cell anal canal carcinoma with pulsed dose rate brachytherapy. Feasibility study of a French cooperative group. Radiother Oncol 1999, 51:129-131.
• [21]López Guerra JL, Lozano AJ, Pera J, Gutiérrez C, Cambray M, Ferrer F, Guedea F: Twenty-year experience in the management of squamous cell anal canal carcinoma with interstitial brachytherapy. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex 2011, 13:472-479.
• [22]Ajani, Jaffer A., Kathryn A. Winter, Leonard L. Gunderson, John Pedersen, Al B. Benson, Charles R. Thomas, Robert J. Mayer, Michael G. Haddock, Tyvin A. Rich, et Christopher Willett. « Fluorouracil, Mitomycin, and Radiotherapy vs Fluorouracil, Cisplatin, and Radiotherapy for Carcinoma of the Anal Canal: A Randomized Controlled Trial ».JAMA 299, no 16 (April 2008): 1914-21. doi:10.1001/jama.299.16.1914.
• [23]Kachnic LA, Tsai HK, Coen JJ, Blaszkowsky LS, Hartshorn K, Kwak EL, Willins JD, Ryan DP, Hong TS: Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol 2012, 82:153-158.
• [24]Peiffert D, Tournier-Rangeard L, Gérard J-P, Lemanski C, François E, Giovannini M, Cvitkovic F, Mirabel X, Bouché O, Luporsi E, Conroy T, Montoto-Grillot C, Mornex F, Lusinchi A, Hannoun-Lévi J-M, Seitz J-F, Adenis A, Hennequin C, Denis B, Ducreux M: Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol 2012, 30:1941-1948.
• [25]Wagner J-P, Mahe MA, Romestaing P, Rocher FP, Berger C, Trillet-Lenoir V, Gerard J-P: Radiation therapy in the conservative treatment of carcinoma of the anal canal. Int J Radiat Oncol 1994, 29:17-23.
• [26]Roed H, Engelholm SA, Svendsen LB, Rosendal F, Olsen KJ: Pulsed dose rate (PDR) brachytherapy of anal carcinoma. Radiother Oncol 1996, 41:131-134.
• [27]Kapp KS, Geyer E, Gebhart FH, Oechs AC, Berger A, Hebenstreit J, Stoeger H: Experience with split-course external beam irradiation?±?chemotherapy and integrated Ir-192 high-dose-rate brachytherapy in the treatment of primary carcinomas of the anal canal. Int J Radiat Oncol 2001, 49:997-1005.
• [28]Kapp KS, Kapp DS, Stuecklschweiger G, Berger A, Geyer E: Insterstitial hyperthermia and high dose rate brachytherapy in the treatment of anal cancer: A phase I/II study. Int J Radiat Oncol 1994, 28:189-199.
• [29]Oehler-Jänne C, Huguet F, Provencher S, Seifert B, Negretti L, Riener M-O, Bonet M, Allal AS, Ciernik IF: HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol Off J Am Soc Clin Oncol 2008, 26:2550-2557.
• [30]Provencher S, Oehler C, Lavertu S, Jolicoeur M, Fortin B, Donath D: Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma. Radiat Oncol 2010, 5:41. BioMed Central Full Text
• [31]Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, Arnold D: Anal cancer: ESMO¿ESSO¿ESTRO clinical practice guidelines for diagnosis, treatment and follow-up.Radiother Onco. 111, no 3 (June 2014): 330-39. doi:10.1016/j.radonc.2014.04.013.